Publikationen

Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaugnessy JA.
The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer..
Breast Cancer Res treat. 2009; 116(3):521-7.
Poellinger A, Martin JC, Ponder SL, Freund T, Hamm B, Bick U, Diekmann F.
Near-infrared laser computed tomography of the breast first clinical experience..
Acad Radiol. 2008; 15(12):1545-53.
Engelken FJ, Meyer H, Juran R, Bick U, Fallenberg E, Diekmann F.
Intra-individual comparison of average glandular dose of two digital mammography units using different anode/filter combinations..
Acad Radiol. 2009; 16(10):1272-80.
Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK.
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers..
J Clin Oncol. 2009; 27(35):5887-92.
Diekmann F, Freyer M, Diekmann S, Fallenberg EM, Fischer T, Bick U, Pöllinger A.
Evaluation of contrast-enhanced digital mammography..
Eur J Radiol. 2009;
Chen W, Giger ML, Newstead GM, Bick U, Jansen SA, Li H, Lan L.
Computerized asessment of breast lesion malignancy using DCE-MRI robustness study on two independent clinical datasets from two manufactures..
Acad Radiol. 2010; 17(7):822-9.
Müller-Schimpfle MP, Heindel W, Kettritz U, Schulz-Wendtland R, Bick U.
Consensus Meeting of Course Directors in Breast Imaging, 9 May 2009, in Frankfurt am Main. - Topic: Masses..
Rofo. 2010;
Darb-Esfahni S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budszies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy..
Breast Cancer Res. 2009; 11(5):R69.
Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G.
Tumor-associated lymhocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer..
J Clin Oncol. 2010; 28(1):105-13.
Eucker J, Emde A, Possinger K.
Treatment of breast cancer: from hormones to antibodies..
Internist (Berl). 2006; 47(12):1223-4.

Jubiläumsjahr 2010

Jubiläumslogo Charité 300

Die Charité wird 300 Jahre alt. Mehr...

Kennen Sie schon die Charité 300 Collection?